226 filings
Page 4 of 12
8-K
7ehmcmn
29 Oct 20
Regulation FD Disclosure
5:19pm
8-K
wcryh auzu5o
27 Oct 20
NeoGenomics Reports Revenue Growth of 20% to Record $125 Million
7:59am
8-K
pxqyu x5h
31 Jul 20
INVESTOR PRESENTATION July 2020
5:10pm
8-K
738hcw
28 Jul 20
NeoGenomics Reports Revenue of $87 Million
8:18am
8-K
85e1yr4w
20 Jul 20
NeoGenomics Announces Board Appointments
5:06pm
8-K
x5cq4ls
23 Jun 20
Departure of Directors or Certain Officers
5:00pm
8-K
blvtffhft47lbg
3 Jun 20
Departure of Directors or Certain Officers
4:41pm
8-K
u5ax34unu2ia
27 May 20
NeoGenomics Enters Strategic Collaboration with Inivata to Commercialize InVisionFirstĀ®-Lung Liquid Biopsy Test
5:08pm
8-K
19q8t pfh4fxi
4 May 20
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
5:18pm
8-K
axun8s1p8bii q6d
30 Apr 20
NeoGenomics Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
12:00am
8-K
538zsw
28 Apr 20
NeoGenomics Reports 11% Revenue Growth to $106 Million
8:15am
8-K
ze36lu3w7nchnej3
17 Apr 20
Improving Patient Care 2019 Annual Report
4:55pm
8-K
ws9vdrv
9 Apr 20
NeoGenomics Provides COVID-19 Business Update
5:12pm
8-K
5qryduuxhipd 63hldy6
2 Mar 20
INVESTOR PRESENTATION February 2020
5:19pm
8-K
l3n0 hy78c99wghe
27 Feb 20
NeoGenomics Reports 40% Revenue Growth to $107 Million
8:09am
8-K
7h0b39o
11 Feb 20
Departure of Directors or Certain Officers
5:06pm
8-K
ztrtw4wgq a05y
13 Jan 20
NeoGenomics Acquires Oncology Division from Human Longevity for $37 Million
4:50pm
8-K
yn4gr24
2 Dec 19
Departure of Directors or Certain Officers
5:07pm
8-K
0bt4gh6r0
31 Oct 19
INVESTOR PRESENTATION October 2019
12:00am
8-K
cts mvnzadc
29 Oct 19
NeoGenomics Reports 51% Revenue Growth to $105 Million
7:38am